Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
It has a license agreement with Meros.
The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 12, 25 | -0.10 Increased by +16.67% | -0.08 Decreased by -25.00% |
Mar 31, 25 | -0.09 Increased by 0.00% | -0.12 Increased by +22.88% |
Nov 12, 24 | -0.18 Decreased by -100.00% | -0.08 Decreased by -125.00% |
Aug 12, 24 | -0.10 Increased by +16.67% | -0.13 Increased by +23.08% |
Apr 1, 24 | -0.12 Decreased by -9.09% | -0.12 |
Mar 28, 24 | -0.09 Increased by +25.00% | -0.09 |
Nov 14, 23 | -0.09 Increased by +30.77% | -0.12 Increased by +25.00% |
Aug 10, 23 | -0.12 Decreased by -20.00% | -0.12 |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Mar 31, 25 | 0.00 Decreased by N/A% | -8.29 M Increased by +9.72% | Decreased by N/A% Decreased by N/A% |
Dec 31, 24 | 0.00 Decreased by N/A% | -8.18 M Decreased by -7.09% | Decreased by N/A% Decreased by N/A% |
Sep 30, 24 | 0.00 Decreased by N/A% | -12.73 M Decreased by -114.64% | Decreased by N/A% Decreased by N/A% |
Jun 30, 24 | 0.00 Decreased by N/A% | -6.59 M Increased by +11.79% | Decreased by N/A% Decreased by N/A% |
Mar 31, 24 | 0.00 Decreased by N/A% | -9.18 M Decreased by -29.49% | Decreased by N/A% Decreased by N/A% |
Dec 31, 23 | 0.00 Decreased by N/A% | -7.64 M Decreased by -1.62% | Decreased by N/A% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by N/A% | -5.93 M Increased by +25.61% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by N/A% | -7.47 M Decreased by -15.14% | Decreased by N/A% Decreased by N/A% |